1. Australia Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Anagenics Limited

Anagenics Limited

AN1.AX
Anagenics LimitedAU flagAustralian Securities Exchange
0.01
AUD
- -
- -
3.07MMarket Cap
Anagenics Limited
AN1.AX
(Australian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
0.01
0.02
0.06
0.04
0.06
0.08
0.09
0.09
0.07
0.04
0.04
0.03
0.03
0.01
Revenue per Share
-0.09
-0.12
-0.09
-0.05
-0.04
-0.08
-0.07
-0.08
-0.06
-0.07
-0.05
-0.02
-0.02
-0.01
-0.02
- -
Basic EPS, GAAP
-0.08
-0.12
-0.08
-0.05
-0.06
-0.08
-0.05
-0.07
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.08
0.02
0.02
0.11
0.1
0.05
0.04
0.04
-0.01
0.06
0.08
0.07
0.04
0.03
0.01
- -
Book Value per Share
0.19
0.11
0.09
0.1
0.1
0.05
0.05
0.05
- -
0.05
0.08
0.06
0.02
0.02
- -
- -
Tangible Book Value per Share
15
19
23
31
38
42
49
55
60
82
106
143
211
266
399
469
Basic Weighted Avg Shares
- -
- -
- -
1
2
2
3
4
6
7
7
6
9
9
11
5
Sales/Revenue/Turnover
- -
-8,887.48
-1,941.59
-472.02
-127.28
-239.99
-153.27
-114.44
-78.68
-96.29
-87.14
-77.78
-49.4
-25.63
-68.28
-27.8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
1
- -
Depreciation Expense
-1
-2
-2
-2
-1
-3
-3
-4
-4
-6
-5
-3
-4
-3
-8
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-7,224
-1,395.45
-281.9
-67.09
-181.1
-112.13
-99.42
-66.09
-80.93
-66.49
-58.23
-39.51
-29.27
-71.68
-26.04
Profit Margin (%)
3
2
2
3
4
2
3
3
2
4
8
9
5
5
2
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
LT Debt
3
2
2
5
6
4
5
4
2
6
10
10
8
9
3
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-292.4
-542.8
-82.03
-40.24
-113.53
-172.03
-214.67
- -
- -
-70.62
-37.26
-40.46
-30.79
-134.01
-53.11
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.18%
-21.8%
-32.6%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
11.36%
11.23%
-84.04%
Sales/Revenue/Turnover
16.81%
-0.26%
-56.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
5

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Tokyo Lifestyle Co., Ltd. (TKLF)
Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ)
Tittot Company Limited (9949.TWO)
Hercules S.A. - Fábrica de Talheres (HETA4.SA)
Reckitt Benckiser Group PLC (3RB.DE)
Hindustan Unilever Limited (HINDUNILVR.NS)
Business
Anagenics Limited (ASX:AN1) operates as an Australia-based health and beauty-tech company focused on the beauty, health, and wellness sector, developing, manufacturing, and marketing premium branded consumer products including anti-ageing hair care under the Evolis brand, skin, hair, and body care under the Uspa brand, and distributing leading skincare and beauty products through its subsidiary BLC Cosmetics to spas, clinics, salons, retail stores, and online channels; it serves wholesale and retail customers via omnichannel distribution primarily in Australia, New Zealand, the Pacific Islands, and Japan. Founded in 2004 and headquartered in Sydney, the company originally started as a biotechnology firm targeting inflammatory diseases and hair loss therapies before evolving into its current consumer-focused portfolio emphasizing clinically validated anti-aging solutions for hair, skin, and body to help consumers live longer in good health. Recent developments include a Midkine Antibody Licensing Deal in May 2024, a licensing partnership announced in July 2024 driving 16% FY2024 revenue growth, completion of the Face Medi Group sale in October 2024, ongoing corporate restructuring updates through December 2024 involving FOS Capital, director resignations, trading suspensions in September 2024, and a proposed securities issue in January 2025.